In essential hypertension (ESS) whole body and vascular nitric oxide (NO) synthesis is generally thought to be reduced. We therefore investigated the systemic and renal responses to acute treatment with N G -monomethyl-L-arginine (L-NMMA), a competitive NOS-inhibitor, in 12 patients with ESS and 18 healthy controls (CON) in a randomized, placebo-controlled study. Main effect parameters were renal hemodynamics (glomerular filtration rate [GFR] and renal plasma flow [RPF]), systemic blood pressure (BP), and fractional excretions of sodium (FE Na ) and lithium (FE Li ). Experiments were performed on two occasions for each subject studying the effects of either L-NMMA (3 mg/kg intravenously) or placebo. The patients with ESS were studied after at least 14 days off antihypertensive medication. Renal hemodynamics were assessed by the clearances of 125 I-hippuran (RPF) and 51 Cr-EDTA (GFR). The L-NMMA induced a significant increase in systemic BP and significant reductions in RPF, FE Na , and FE Li in both groups. The increase in diastolic BP was significantly attenuated in ESS (ESS: 8% Ϯ 2% v CON: 14% Ϯ 2%, P Ͻ .05). The GFR and RPF were equally reduced by L-NMMA in both groups (RPF ESS : Ϫ19% Ϯ 4% v RPF CON : Ϫ15% Ϯ 3%, P ϭ not significant [NS]). However, the reduction in FE Na was enhanced in ESS (ESS: Ϫ42% Ϯ 7% v CON: Ϫ25% Ϯ 3%, P Ͻ .01). The FE Li decreased equally in both groups (ESS: Ϫ17% Ϯ 2% v CON: Ϫ17% Ϯ 6%, P ϭ NS). It is concluded that acute NO blockade in ESS is accompanied by a reduced systemic pressor response, an unchanged renal hemodynamic response, and an enhanced reduction in FE Na . The results suggest that patients with essential hypertension are highly dependent on NO to maintain sodium excretion. T he vasodilator molecule nitric oxide (NO) is continuously released from endothelial cells throughout the vascular system including the renal vasculature, and it is an important regulator of vasodilatory tone. In addition, NO operates in the brain to influence sympathetic activity in vasomotor centers and in the kidneys to promote renal vasodilatation and sodium excretion. Nitric oxide therefore influences long-term blood pressure (BP) regulation profoundly and through several mechanisms.
T he vasodilator molecule nitric oxide (NO) is continuously released from endothelial cells throughout the vascular system including the renal vasculature, and it is an important regulator of vasodilatory tone. In addition, NO operates in the brain to influence sympathetic activity in vasomotor centers and in the kidneys to promote renal vasodilatation and sodium excretion. Nitric oxide therefore influences long-term blood pressure (BP) regulation profoundly and through several mechanisms. 1 Patients with essential hypertension have reduced levels of NO bioactivity in the systemic circulation, both with regard to basal NO activity and impaired ability to increase NO bioactivity with NO stimulatory maneuvers. 2, 3 Renal NO activity in human hypertension has not been equally well characterized. Previous human studies did not include data on sodium excretion or placebo intervention. To characterize the significance of basal renal NO activity in human essential hypertension we investigated the renal effects of acute systemic treatment with N G -monomethyl-L-arginine (L-NMMA), which is a competitive inhibitor of NO synthesis, in patients with essential hypertension and in healthy control subjects in a randomized, placebo-controlled study. The main effect parameters were renal hemodynamics, renal sodium excretion, systemic BP, and plasma levels of components of the renin-angiotensin system (RAS), the natriuretic peptides, and cGMP, which is a common second messenger for both the natriuretic peptides and NO activity.
Materials and Methods

Patients and Study Design
The study was approved by the local ethics committee and The Danish National Board of Health. Informed consent was obtained from all participating subjects. Twelve patients with essential hypertension (ESS) and 18 healthy control subjects (CON) were included. The study included both men and women, aged Ͻ65 years and body weight Ͻ100 kg. All patients had well-established hypertension by 24-h ambulatory BP monitoring, and secondary causes of hypertension had been excluded by conventional laboratory criteria, renography, and renal Doppler ultrasound. Patients with a plasma (P) creatinine Ͼ250 mol/l, proteinuria Ͼ300 mg/d, hematuria, a history of stroke, congestive heart failure, liver disease, hematologic or endocrine disease were excluded. All patients were on antihypertensive medication at recruitment and were tapered off treatment for at least 14 days before the experiments. Medication included different combinations of angiotensin-converting enzyme inhibitors (7 patients), calciumchannel blockers (8 patients), ␤-blockers (8 patients), diuretics (9 patients), and ␣-blockers (1 patient). Control subjects were required to have no history of disease of the heart, liver, kidneys, or endocrine organs, no history of alcohol or drug abuse, and not currently under medical treatment. Before study entry all participants had a clinical examination, BP measurement, electrocardiogram, and laboratory screening, including hematology, P-electrolytes, P-creatinine, blood (B) glucose, P-cholesterol, P-bilirubin, P-alkaline phosphatase, P-alanine aminotransferase, and prothrombine time. Urine was analyzed by dip-stick. The results of these tests were required to be normal before inclusion.
The study was performed as a randomized, placebocontrolled, crossover investigation. Each subject was studied on two separate occasions with at least 14 days in between. On each study day either L-NMMA or placebo was administered in randomized order with all other procedures and measurements being identical.
Clearance Experiments
All subjects were treated with a tablet of 2 g/d of sodium chloride for 3 days before the experiments and were instructed to fast overnight. A tablet of lithium carbonate (300 mg) was ingested at 10 PM the night before for the measurement of lithium clearance. An oral water load of 200 mL of tap water every 30 min was started at 7 AM. Two indwelling catheters for blood sampling and administration of tracers and study drugs were placed in forearm veins, one in each arm. Urine was collected by voiding in the standing or sitting position, and the subjects were otherwise kept in the supine position. At 8:30 AM priming doses of 51 Cr-EDTA and 125 I-hippuran were given followed by sustain infusions of both. After an equilibration of 60 min the study continued with clearance periods of 30 min. Three baseline periods were obtained from 9:30 to 11 AM. At 11 AM, bolus injection of either L-NMMA or placebo was given during 10 min. The study continued with four clearance periods to evaluate the effects of treatment. Blood samples were drawn every 30 min (ie, before the first clearance period and at the end of each period) and were analyzed for tracers, standard electrolytes, lithium, and osmolality. In addition, analysis of the plasma levels of cGMP, renin, angiotensin II (Ang II), aldosterone (ALDO), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP) were performed from blood samples drawn at 11 AM (baseline), at noon (60 min after treatment), and at 1 PM (120 min after treatment, end of experiment). Urine collections were analyzed for tracers, standard electrolytes, lithium, osmolality, and cGMP (U-cGMP).
Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured by the constant infusion clearance technique using 51 Cr-EDTA (GFR) and 125 I-hippuran (RPF) as reference substances. A priming dose ensured a serum activity of 200 to 600 cpm/mL for 51 Cr-EDTA and 800 to 1600 cpm/mL for 125 I-hippuran. Serum activity was kept stable by constant intravenous infusion with a volume-controlled infusion pump. Blood pressure was determined by a semiautomatic, oscillometric device. Blood pressures were measured every 15 min, except after L-NMMA/placebo when pressures were measured every 5 min for 30 min.
Biochemical Measurements
Cyclic GMP, renin, Ang II, ALDO, ANP, and BNP were measured by previously described methods. 4 -8 Serum and urinary concentrations of lithium were measured by atomic absorption spectrophometry (Perkin Elmer 3100, Perkin Elmer, Boston, MA). Plasma and urinary concentrations of sodium and potassium were measured by routine methods at the Department of Clinical Chemistry, Holstebro Hospital.
Study Drug
L-NMMA was obtained from Clinalfa, Laüfelingen, Switzerland.
Calculations and Statistics
The clearance calculations were based on standard formulas. Renal vascular resistance (RVR) was estimated as mean arterial BP (MAP)/(RPF/1 Ϫ hematocrite (htc)). All results are given as means Ϯ SEM. Within-group comparisons and analysis of time-series were performed by repeated measures analysis of variance (ANOVA) or paired Student t tests with Bonferoni correction where appropriate. Effects of L-NMMA versus placebo were primarily analyzed by repeated measures two-way ANOVA with treatment as factor. Between group comparisons were performed by repeated measures two-way ANOVA over time with patient group as factor or independent samples t tests with Bonferoni correction where appropriate.
Comparisons between groups of L-NMMA treatment were based on relative changes from baseline after subtraction of the placebo response (placebo correction). The placebo-corrected values were calculated as the relative response to placebo from baseline subtracted from the relative response to L-NMMA from baseline in each subject. P Ͻ .05 was considered the limit of significance.
Results
Demographics
Baseline characteristics of the ESS and CON groups are shown in Table 1 . No major difference appeared with regard to age, gender, and body size. The ESS group showed a slightly decreased plasma K ϩ . Overall sodium balance was equal. Fig. 1 depicts relative changes after L-NMMA in placebocorrected systolic BP, diastolic BP, and heart rate (HR). L-NMMA induced significant increases in systolic and diastolic BP and a significant decrease in HR, lasting approximately 20 to 30 min in both groups. The maximal significant changes in systolic and diastolic BP occurred 10 min after the L-NMMA infusion. Likewise, HR decreased significantly after 10 min. The relative increase in diastolic BP was significantly attenuated in ESS but not systolic BP and HR (Fig. 1) . Placebo was not accompanied by major significant changes in systemic hemodynamics (data not shown).
Blood Pressure and Heart Rate Response
Renal Hemodynamics
Absolute values of GFR, RPF, and RVR are shown in Table 2 . Relative changes after L-NMMA administration corrected for the placebo response for GFR and RPF are depicted in Fig. 2 . Both GFR and RPF were significantly lower in ESS than in CON at baseline (Table 2) . L-NMMA treatment induced small and similar decrements in GFR in both groups. Small, significant decreases in GFR were also noted after placebo in CON. The GFR response to L-NMMA was significant from placebo only in the ESS group. However, all changes were small, and placebo-corrected responses were not significantly different between ESS and CON (Fig. 2) . Renal plasma flow decreased significantly and to a similar extent after L-NMMA in both groups and remained stable after placebo ( Table 2 ). The RPF response to L-NMMA was significantly different from placebo in both groups. The decrease in RPF lasted for approximately 90 min in both groups. There was no difference between the L-NMMA-induced changes in RPF between ESS and CON (Fig. 2) .
Renal vascular resistance increased significantly and to a similar extent in both groups after L-NMMA administration and remained stable after placebo (Table  2 ). In both groups the response was significantly different from placebo ( Table 2 ). The changes in RVR after L-NMMA were not different between ESS and CON (data not shown).
Renal Sodium and Lithium Excretion
Absolute values of sodium excretion (U Na V), fractional sodium excretion (FE Na ), and fractional lithium excretion (FE Li ) are shown in Table 3 . Relative changes after L-NMMA corrected for the placebo response are depicted in Fig. 3 .
Baseline values of U Na V and FE Na were not significantly different between groups. Sodium excretion decreased profoundly in both groups after L-NMMA administration, both in terms of U Na V and FE Na and the effect was evident for 90 min. Both U Na V and FE Na were stable after placebo except for a minor decrease in U Na V (CON) after 30 min (Table 3) . Maximal decreases in U Na V and FE Na occurred after 30 min. In both cases these responses were highly significant from placebo ( Table 3) . The decreases in U Na V and FE Na after L-NMMA administration were significantly enhanced in the ESS compared to the CON group after correction for the placebo responses (Fig. 3) .
Baseline FE Li were significantly higher in the ESS than in the CON group on both study days (Table 3) . L-NMMA induced a significant decrease in FE Li in both groups, which was significant at least 60 min after treatment. The response was significant from placebo, where values remained stable, in both groups ( Table 3) . The response to L-NMMA was of a similar magnitude after placebo-correction in the ESS and the CON groups (Fig. 3) .
Plasma Hormones
Absolute values of plasma hormone levels are shown in Tables 4 and 5 . Plasma levels of the components of RAS were equal at baseline (Table 4) . L-NMMA induced a significant decrease in plasma renin in both CON and ESS groups, which was not seen after placebo administration. Placebo-corrected responses for renin after L-NMMA were not different between ESS and CON groups (data not shown). No major changes or differences between ESS and CON groups were noted with regard to Ang II and ALDO, apart from a small increase in Ang II in the CON group after placebo administration. Plasma levels of ANP, BNP, and cGMP were slightly elevated in the ESS group (Table 5) at baseline. After L-NMMA administration, only plasma and urinary cGMP decreased significantly both in the ESS and the CON groups, but the overall responses did not differ significantly from placebo.
Discussion
In a randomized placebo-controlled study we investigated the effects of NO inhibition with L-NMMA on renal and systemic hemodynamics and renal tubular functions in patients with ESS versus a control group. The main findings in ESS patients were an enhanced sodium retention response along with unaffected renal hemodynamics and a slightly reduced systemic pressor response. These findings suggest, to some extent, that systemic but not renal NO availability is decreased in patients with essential hypertension. Two studies have investigated the renal hemodynamic effects of systemic NO inhibition in patients with essential hypertension compared to healthy controls. Jacobi et al 9 studied the effects of L-NMMA on RPF, GFR, and MAP in 39 essential hypertensives and 32 controls. They found a similar reduction in RPF and increase in MAP as in the present study with no difference between the treatment groups. The investigators used the same dose of L-NMMA as in the present study, but a longer infusion period. Using another NO inhibitor (L-NAME), van den Meiracker et al 10 studied the effects of systemic NO inhibition on renal and systemic hemodynamics in 10 patients with essential hypertension and 10 controls. These investigators again found no difference in the renal hemodynamic response to L-NAME between hypertensives and controls. Our findings confirm observations from these previous studies with regard to the preserved renal hemodynamic response to NO inhibition. We also observed a slightly reduced systemic (diastolic) pressor response in ESS patients. A similar tendency was observed in the study by van den Meiracker et al. The finding is in agreement with observations from human plethysmographic forearm studies showing a depressed L-NMMA response in patients with essential hypertension in the forearm vasculature. 11, 12 The present study was strengthened by including a placebo intervention and by including data on renal sodium handling. Furthermore, we induced a mild sodium load with sodium tablets to enhance the expected sodiumretaining effects of L-NMMA. 13 It was found that the sodium retention response after L-NMMA administration was enhanced in ESS patients, both in terms of U Na V and FE Na . This was an unexpected finding considering the belief that NO synthesis is generally reduced in hypertension. 3 Our data do not provide a definite explanation for this observation. It was noted that FE Li was increased in ESS patients at baseline and that FE Li decreased similarly after L-NMMA in both groups. Taken together these observations suggest that ESS patients have a relatively reduced proximal sodium reabsorption at baseline, and that the major difference in the response to L-NMMA lies in the distal parts of the nephron. It is not clear from these data whether this difference is caused by an increased intrarenal NO availability in ESS or a more indirect mech- anism as we did not attempt to measure NO levels directly. Most likely, it is the result of the effect of L-NMMA on several mechanisms ultimately affecting distal tubular sodium handling. It is known that NO influences virtually all renal processes being involved in the maintenance of sodium balance. These include the tubuloglomerular feedback response, macula densa signaling and rennin secretion, regulation of medullary blood flow, and a wide range of sodium transporters along the tubular system, both proximally and distally. 14 -16 Recently, evidence has been put forward that O 2 Ϫ (superoxide) acts in concert with NO to regulate sodium reabsorption in the thick ascending limb of the loop of Henle. 17 Removal of NO in this system leads to enhanced sodium reabsorption driven by O 2 Ϫ . Superoxide is believed to be increased in hypertension and the production of this highly reactant molecule is particularly high in the renal medulla. 17 Thus, it possible that the present findings reflect a disrupted balance between NO and O 2 Ϫ in ESS patients. Finally, it could be speculated that the enhanced sodium response was due to an exaggerated renal vasoconstriction mediated by autoregulatory forces due to the abrupt effect of L-NMMA, although this could not be detected by the clearance data. However, animal experiments have shown similar effects of NO inhibition on sodium excretion with and without servocontrol of renal perfusion pressure. 18 The activity of the RAS (ie, renin, Ang II, and ALDO) was relatively suppressed to a similar extent in both groups. L-NMMA induced similar decreases in renin levels in both groups. This response has been described in earlier studies in healthy subjects, 4, 13, 19, 20 It is noteworthy that our findings of the activity of the RAS cannot explain the observed differences in the sodium response because the overall RAS response to L-NMMA was not changed in ESS patients. The relative frequent change in body position during our clearance experiments (ie, standing up to void each 30 min) could be a confounder of the RAS analyses by influencing the levels of renin and Ang II. However, the standing period was not allowed to exceed more than a few minutes and it is unlikely that postural changes of such short duration would influence renin levels significantly.
We used L-NMMA to inhibit NO in this study. This substance is an unselective NO synthase (NOS) inhibitor with equal affinity toward the three known isoenzymes of NOS. We therefore cannot make any suggestions of the relative impact of L-NMMA on any of these isoenzymes. In addition, we cannot precisely evaluate how much renal NO in fact was removed by the L-NMMA intervention.
The present study demonstrates and confirms in a randomized and placebo-controlled design that the systemic diastolic pressor response to NO inhibition is attenuated in ESS but the renal vascular response is intact. It is furthermore shown for the first time that acute sodium retention elicited by NO inhibition is enhanced in ESS after a mild sodium load. Based on these findings we suggest that basal renal perfusion and renal sodium excretion are profoundly NO dependent in human essential hypertension. It is unclear whether this is due to changes in intrarenal NO availability or indirect mechanisms such as the interaction with superoxide. Regardless of the mechanism the results suggest that patients with essential hypertension are highly dependent on NO to maintain sodium excretion.
